James Huang - 29 May 2026 Form 4 Insider Report for Connect Biopharma Holdings Ltd (CNTB)

Reporting relationship: Director
Issuer ticker: CNTB
Reported as of: 29 May 2026
Net transaction value: +$371,610
SEC form: 4
Accepted by SEC: 02 Jun 2026, 16:30:20 UTC
Prior SEC filing: 01 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ James Huang

Key filing fact

James Huang filed Form 4 for Connect Biopharma Holdings Ltd (CNTB) on 02 Jun 2026.

Key facts

This page summarizes James Huang's Form 4 filing for Connect Biopharma Holdings Ltd (CNTB).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 02 Jun 2026, 16:30.

Change

Previous filing in this sequence was filed on 01 Apr 2026.
Current net transaction value: +$371,610.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001573160 Primary reporting owner

Huang James

Relationship: Director
Address: C/O PANACEA CAPITAL, 79 SCIENCE PARK DRIVE, #04-05, SINGAPORE, SINGAPORE
Signature: /s/ James Huang
Signature date: 02 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CNTB transaction

Ordinary Shares

Purchase

Transaction value: $371,610
Shares: +150,000
Change %: +1.1%
Price: $2.48
Shares after: 13,310,000
Date: 29 May 2026
Ownership: See Footnote
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $2.37 to $2.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

Footnote F2

Panacea Venture Healthcare Fund II, L.P. is the record holder of the Ordinary Shares reported herein. James Huang is the sole owner of Panacea Innovation Limited, which is the sole owner of Panacea Venture Healthcare Fund II GP Company, Ltd., which is the general partner of Panacea Venture Healthcare Fund II, L.P. As a result, James Huang may be deemed to share beneficial ownership of the Ordinary Shares reported herein, but disclaims such beneficial ownership.